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isolated from rats were cannulated at a pressure of 40mmHg.Changes in internal diame- 
ter were examined with videomicroscopy. We tested the response dose-dependently to 
Y27632, a specific inhibitor for the Rho associated protein kinasa, in the presence of pre- 
contracted by PE. The precontraction of PE in CHF was significantly induced by low con- 
cantration than controls (10-7M vs 10-6M). The response to Y27632(10-7M, 3X10-6M, 
10-6M) of resistance arteries in CHF was more greater than that in controls(53% vs 
23%,70% vs 25%,89% vs 65%,respectively, P<0.01). Y27632 significantly inhibited PE- 
induced contraction in CHF compared with controls. PKC inhibitor had no significant 
effect on femoral arteries in both CHF and control. Conclusions.: The contraction of resis- 
tance arteries by PE were enhanced in CHF compaired with controls. Y27632 signifi- 
cantly inhibited phenylephrine-induced contraction in CHF.Enhancad Ca2+ sensitivity via 
a Rho kinasa-dependent pathway, but not PKC, may be involved enhanced contraction 
of resistance arteries by PE in CHE 
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1032-77 Prevention of Deep Venous Thrombosis on Long-Haul 
Flights 
Giovanni Belcaro. George Geroulakos, Mariateresa De Sanctis, Andrew N. Nicolaides, 
Lucrezia Incandela, Maria Rosada Cesarone, Marco Bucci, Andrew Lennox, Chieti 
Universi~ Pescara/San Valentino, Italy, St Mary's Hospital, London, United Kingdom. 
Background: the LONFLITI+2 studies have established that in high risk subjects after 
long (10-12 hours) flights the incidence of deep venous thrombosis (DVT) is between 4- 
6%. Methods: 400 subjects at high risk for DVT were randomisad into 4 groups to evalu- 
ate two types of prophylaxis in long-haul flights. The CONTROL GROUP: had no prophy- 
laxis; in the ASPIRIN TREATMENT GROUP subjects were treated with 400 mg (tablets) 
of aspirin, 1 dose daily for 3 days, starting 12 hours before the flight); in the LOW 
MOLECULAR WEIGHT HEPARtN (LMWH) GROUP, enoxapadne, one dose was 
injected between 2 and 4 hours before the flight. The dose was weight-adjusted, 1000 
LU. (O.1 ml) par 10 Kgs. in the fourth group prophylaxis was the combination of LMWH 
(dosage as in group 3) and graduated, below-knee stokings. Subjects with potential 
problems due to aspirin or LMWH or at risk of drugs interactions were excluded. 
RESULTS Out of the 100 included subjects in each group a total of 337 subjects com- 
pleted the study. Drop-outs due to low compliance or travelling/connections problems 
were 17%. Age and sex distribution were comparable in the three groups as well as risk 
distributions.. Mean age was 47 (range 28-75; SD 11; 65% males). CONTROL GROUP. 
Out of 82 subjects there were 4.8% of subjects with DV'I" (equivalent to 3.8% of limbs) 
with 2 superficial thromboses; 4.8% of limbs suffered for a thrombotic event. ASPIRIN 
GROUP (84 subjects) 3.6.% of patients had DV'I" (1.8% of limbs); there were 2 superficial 
thromboses (2.9% of limbs had a thrombotic event). In the LMWH group (82 subjects) 
there was no DVT. One superficial thrombosis was documented (0.61% of limbs had a 
thrombotic event) (P<0.002 in comparison with the previous two groups). In the 
LMWH+stockings group (88 subjects) there was no thrombotic event (P<0.002 in com- 
padson with the other groups). In this study 83% of DV'I's were in passengers in non-aisle 
seats. Mild side effects were observed (gastro-intestinal symptoms) in 13% of patients 
under aspirin. Considering these observations one-dose enoxaparin and elastic stock- 
ings are effective options in high-risk subjects, in long-haul flights. 
1032-78 Pulmonary Embolism Associated With Long Haul Air  
Travel 
Susan R. Hertzbero. Shiva Roy, Adam Chan, David Bdeger, Warren Walsh, Prince of 
Wales Hospital Sydney, Australia, St George Hospital, Sydney, Australia. 
BACKGROUND 
The association between long haul air travel and pulmonary embolism (PE) is recogn- 
ised, but the absolute risk has not been quantified. As Australia is geographically iso- 
lated, more than 50% of international travelers arrive at Sydney airport after a long haul 
flight. Patients who become unwell upon disembarkation are taken to one of the two hos- 
pitals in proximity to the airport. In this study we reviewed the presentations at these two 
hospitals in an attempt to quantify the risk of acute PE associated with long hau~ air 
travel. 
METHODS: A retrospective analysis of all patients presenting to the Emergency Depart- 
ments (ED) with PE over a three year period was undertaken and those patients admit- 
ted directly from Sydney's International airport were specifically examined. 
RESULTS: From January 1998 to January 2001, fifteen patients were admitted directly 
from Sydney's international airport to the ED with acute PE confirmed by pulmonary scin- 
tigraphy or spiral CT. All patients had flown for at least 9 hours, the majority had flown 14 
hours from Los Angeles. 
Eight of the nine patients with features of hemodynamic instability and/or right ventdcular 
dilatation received thrombolytic therapy and recovered well. The ninth patient suffered a 
cardiac arrest and died the day after presentation. The six remaining patients had an 
uncomplicated hospital course with conventional anticoagulant therapy. During the 
period of our review 6.6 million passengers arrived in Sydney on long haul international 
flights representing an incidence of 2.3 per million. 
CONCLUSION: The incidence of acute pulmonary embolism associated with long dis- 
tance air travel is low and the majority of patients survive following hospital presentation. 
1032-79 Deep Vein Thrombosis Is Frequent in Asymptomatic 
Patients Entering a Cardiac Rehabilitation Program 
After Coronary Artery Bypass Surgery 
Marco Ambrosetti. Mario Salerno, Mara Zambelli, Filippo Mastropasqua, Daniela 
Scrutinio, Roberto Tramadn, Roberto Pedrefti, S. Maugeri Foundation, Care and 
Research Institute, Tradate (VA), Italy. 
No specific guidelines on venous thromboprophylaxis after cardiac bypass (CABG) have 
been issued as in other surgical subspecialties. Few information are available about the 
prevalence of deep vein thrombosis (DVT) after discharge. 
Aims of this study were 1) to describe current DVT prophylaxis after CABG and 2) to esti- 
mate the rate of DVT in patients with a recent CABG entering a cardiac rehabilitation pro- 
gram. 
Two hundreds and seventy consecutive ambulating asymptomatic patients discharged 
from 19 surgery units (men 82%; mean age 65_+9 years, mean interval after operation 8 
days) underwent bilateral venous ultrasound examination (double-blind test performed 
by two operators) at admission in 3 rehabilitative institutions in Italy. Patients with previ- 
ous DVT or pulmonary embolism (PE), concomitant other cardiac surgery or planned 
anticoagulation were excluded. Testing was repeated 7 days later if the result was normal 
at admission and successively if symptoms occurred during hospitalization. 
31 patients (11%) received no pharmacological or mechanical prophylaxis despite 
absence of major contraindications. In 168 (62%) cases prophylaxis with subcutaneous 
heparin for more than 3 days after CABG or until discharge from surgery unit was 
present, while 102 (38%) cases were prescribed heparin for _<3 days. Graded compres- 
sion stockings (GCS) were prescribed in 76% of cases, bilaterally in 7%. 
DVT was detected in 47 (17.4%) patients, complicated in 2 (0.7%) by symptomatic PE (1 
fatal PE). Proximal DVT was detected in 7 cases (2.6%), while distal DVT accounted for 
remaining 40 (14.8%). In 23 cases (49%), clots were found in the leg contralateral to the 
saphenous vein harvest site. On multivariate analysis the following variables were inde- 
pendently associated with major risk of DVT after CABG: female sex (p<O.001), length of 
stay in surgery unit >8 days (p<0.05) and absence of heparin prophylaxis (p<0.05). 
This study showed a high rate of DVT in ambulating asymptomatic patients admitted to a 
cardiac rehabilitation program after CABG. Wearing monolateral GCS after CABG had 
limited efficacy, as clots were often localized bilaterally. The role of routine heparin pro- 
phylaxis should be extensively investigated. 
1032-80 Is Troponin I a Risk Factor for Poor Outcome in 
Pulmonary Embolism? 
Aimae E. Koraleskv. Bradley Bart, Fred Apple, Timothy D. Henry, Hennepin County 
Medical Center, Minneapolis, Minnesota, University of Minnesota, Minneapolis, 
Minnesota. 
Background: Three small trials have reported a wide range of increased cardiac biomar- 
kers in acute pulmonary embolism (PE): 7.7% CK-MB, 32% troponin T, and 39% troponin 
I (TI). Elevated troponins may be predictive of mortality, right ventricular dysfunction 
(RVD) and poor outcome. RVD has been shown to be a predictor of mortality. We 
reviewed 135 patients (pts) with a confirmed diagnosis of PE in which TI and echocardio- 
grams had been obtained to determine whether TI is a predictor of mortality and poor 
outcome. Various cutoffs of TI positivity were examined to determine the best positive 
predictive value. In addition, RVD was assessed as a risk factor for mortality and poor 
outcome. RVD and TI were compared to determine which is the stronger predictor. 
Methods: 135 consecutive pts with documented PE and TI were identified. 98 pts under- 
went echocardiography during their hospitalization. RVD was defined by RV hypokinesis, 
RV enlargement, or right-sided prominence. In addition to in-hospital death, a poor out- 
come was defined as hemodynamic instability resulting in use of pressors, need for intu- 
bation, or recurrent PE. 
Results: Of the 135 pts, 26 pts died, representing an overall 19% in-hospital mortality 
rate, 24% of pts had peak TI > 0.7 ng/mL, 47% had peak TI _> 0.3 ng/mL, and 53% had 
peak TI > 0.1 ng/mL. TI levels _> 0.7 ng/mL, 0.3 ng/mL, and 0.1 ng/mL resulted in positive 
predictive values of 38%, 25%, and 25% for mortality, respectively (RR 2.97, 1.83, 1.97). 
Negative predictive values for mortality were 87%, 87%, and 86%. Poor outcome 
occurred in 56%, 46%, and 43% (RR 1.7, 1.44, 1.29). In contrast, pts with RVD, regard- 
less of TI, had a 22% mortality rate and poor outcome in 40% (RR 0.89, 0.94). Pts with TI 
> 0.7 had a significant increase in mortality (p < 0.005) and poor outcomes (p < 0.03) but 
TI >_ 0.3, >0.1, and RVD were not significant. TI >_ 0.7 was more often associated with 
death than was RVD (p = 0.125). 
Conclusions: Elevated TI is a predictor of death and poor outcome in PE. A cutoff of 0.7 
ng/mL is more predictive than lower values. TI positivity may be a better predictor of poor 
outcome or death than is RVD. These results have implications for therapeutic options 
such as thrombolytic therapy and should be tested by prospective trials. 
1032-81 Prognostic Significance of Elevated Tropon in  I in Acute 
Pulmonary Embolism 
John A. Sallach. Susan M Sallach, Michael P. Hudson, Mei Lu, James K. McCord, Henry 
Ford Heart and Vascular Institute, Detroit, Michigan. 
Background: Prior studies demonstrate that troponin I (cTnl) and T, sensitive and specific 
markers of cardiac injury, are elevated in some cases of pulmonary embolism (PE). -('he 
purpose of this study was to determine the prognostic significance of elevated cTnl in 
acute PE. 
Methods: Between 1998 and 2000, 287 patients presented to a US tertiary center with 
acute PE diagnosed by VQ scan, spiral CT or pulmonary angiogram. Of these, 177 
(61.7%) had cTnl measured within 24 hours of PE diagnosis using the AxSYM cTnl 
immunoassay (upper limit of normal = 1.0 ng/mL; Abbott Labs). Baseline characteristics 
and outcomes were compared between patients with elevated vs. normal cTnl levels 
using univariate analysis and multivariable adjustment for possible confounders. 
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Results: Fifty-six patients (31.6%) had elevated cTnl > 1.0 ng/mL at the time of PE diag- 
nosis. Patients with elevated cTnl were older (p<0.01) and had higher incidence of malig- 
nancy (p=0.06) but no increased prevalence of prior MI or CAD (p=0.62). Elevated cTnl 
was assoicated with adverse outcomes including 30-d mortality (p<0.01) (Table 1). After 
adjusting for possible confounders, the association of cTnl with adverse outcomes 
remained. 
Conclusions: In the setting of acute PE, elevated cTnl is associated with increased 30-d 
mortality and adverse cardiopulmonary/ hemodynamic outcomes. Elevated cTnl may 
identify high risk patients with PE more likely to benefit from aggressive therapies such 
as thrombolysis. 
Troponin I < 1.1 ng/ Troponin I > 1.0 Adjusted RR P 
mL (n=121) ng/mL (n=56) (95% CI) value 
Peak cTnl 0.3 ± 0.3 6.3 ± 12.4 <0.001 
Age (years) 65.7 ± 16.3 71.9 ± 14.0 <0.01 
Prior MI/Known CAD 25% 21% 0.63 
30-day Mortality 12% 34% 2.2 (1.5,3.3) <0.001 
Hemodynamcic 13% 61% 4.5 (2.7,7.3) <0.001 
Compromise 
Mechanical 17% 48% 2.6 (1.7,4.1) <0.001 
Ventilation 
Pressor Support 9% 36% 2.9 (1.8,4.6) <0.001 
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1033-90 The Angiotensin II Type I Receptor Associated Protein 
ATRAP Is a Transmembrane Protein and Negative 
Modulator of Angiotensin II Signaling 
Marco A. Looez-Ilasaca. Victor J. Dzau, Brigham & Women's Hosp., Boston, 
Massachusetts, Harvard Medica/ School, Boston, Massachusetts. 
AT1 receptor-associated protein (ATRAP) was identified by our group in a yeast two- 
hybrid screen for proteins that bound to the carboxyl-terminal cytoplasmic domain of the 
Angiotensin II type 1 receptor (AT1). In this work we characterize ATRAP as a transmem- 
brane protein, localized in the endoplasmic reticulum and plasma membrane that func- 
tions as a negative modulator of Angiotensin II-induced signal transduction. Endogenous 
and transfected ATRAP cDNA shows a particulate distribution; hydrophobicity analysis of 
the primary structure of ATRAP reveals the presence of three transmembrane domains 
at the amino terminal of the protein and a hydrophilic cytoplasmic carboxyl-terminal tail 
Over-expression of ATRAP mutants show that the deletion of the C-terminal domain of 
ATRAP leads to the formation of prominent perinuctear vesicle clusters, whereas the 
deletion of the N-terminal transmembrane domains leads to a diffuse cytoplasmic distri- 
bution of the protein. Electron microscopy reveals the presence of ATRAP in prominent 
perinuclear vesicular membranes; colocalization analysis by immunofluorescence show 
that ATRAP colocalize in the same vesicular compartment of the endoplasmic reticulum 
marker DiOC6(3). Real time following of ATRAP vesicles shows constitutive translocation 
towards the plasma membrane. Using epitope tagged forms of ATRAP either at the 
amino or carboxyl ends of the molecule, we determined the orientation of the amino end 
as being outside the cell. Functional analysis of the effects of ATRAP on Ang-tl induced 
AT1 receptor signaling reveals a moderate decrease in the generation of inositol lipide, a 
marked decrease of the Ang II-stimulated transcriptional activity of the c-foe promoter 
luciferase reporter gene, and decrease in cell proliferation. These results implicate 
ATRAP as a modulator of AT1 receptor signaling acting in a vesicular compartment, via 
interactions with the C-terminal domain of the receptor. 
1033-91 Mechanisms of Thromboxane A 2 Associated Apoptosis 
in Adult Cardiac Myocytes: Role of Protein Kinase C 
Zeta Mediated Downregulation of Akt Activity 
Yukitaka Shizukuda, Jayant Bagai, Mary E. Reyland, Peter M. Buttdck, University of 
Illinois at Chicago, Chicago,///inois, University of Colorado, Denver, Colorado. 
Background: Apoptosis (Apo) is seen in myocardium exposed to acute ischemic insults 
and Apo may be in part mediated by increased thremboxane A2 (TXA) level. We investi- 
gated the role of protein kinase C (PKC) in Apo induced by TXA. Methods: Adult rat ven- 
tricular myocytes (ARVM) were cultured for 48 h before pharmacological interventions. 
The involvement of PKC was measured with both translocation and immune complex 
kinase assay. Akt activity was measured with both immunoblotting and immune complex 
kinase assay, The extent of apoptosis was assessed with TUNEL and DNA ladder assay. 
Results: Treatment with a TXA mimetic, IBOP for 24 h induced Apo in ARVM in a dose- 
dependent fashion (35.0±3.0% in 100 nM IBOP vs. 13.9±1.6% in controls, P<0.05, data 
expressed as %TUNEL positive cells). The Apo by TXA was completely inhibited by a 
TXA receptor specific inhibitor SQ29548. TXA stimulation resulted in membrane translo- 
cation of PKC~ at 3 min and 1 h stimulation, but not PKC~, LSII, 5, and E. The isoenzyme 
specific activation of PKC~ was confirmed by an immune complex kinase assay. The 
activation of PKC~ by TXA was also associated with reduction of Akt activity. A cell per- 
meable PKC~ specific pseudosubstrate peptide (~PS; a gift from Dr. Mochly-Rosen, 
Stanford University, CA) inhibited apoptosis by TXA at a dose which inhibited TXA-medi- 
ated increase in PKC£~ activity (1 ~M). ~PS also prevented Akt reduction by TXA. The 
anti-apoptotic effect of ~PS was completely abolished by phosphatidylinositol 3-kinase 
inhibitors which inhibit ~PS mediated preservation of Akt activity. In addition, moderate 
PKC~ overexpression for 36 h by adenovirus vector (4.5-fold control) reduced Akt activity 
to half as well as exaggerated apoptosis by TXA (40.8±3.5% with 100 nM IBOP, P<O.05 
vs. 100 nM IBOP alone). 
Conclusion: The activation of PKC~ by thromboxane A2 suppresses Akt activity which in 
turn, promotes apoptosis in adult cardiac myocytes. Therefore, PKC~ specific inhibition 
and/or activation of Akt might be useful in preventing thromboxane A2 mediated cardiac 
injury. 
1033-92 St imulat ion  of  Cyc l ic  AMP Synthesis by Combined 
Overexpression of the Nucleoside Diphosphate Kinase 
NM23H2 and the Alpha-Subunit of Gs Proteins 
Feravdoon Niroomand. Hans-Joerg Hippe, Susanne Lutz, Katrin Knorr, Matthias 
Meyborg, University of Heidelberg, Heidelberg, Germany. 
Background: G proteins are mediators of signalling pathways that are implicated in the 
development of cardiac hypedrophy and dilation. We have recently suggested a recep- 
tor-independent mechanism of G protein activation by a membrane-associated nucleo- 
side diphosphate kinase (NDPK). In saroolemmal membranes from failing human hearts, 
the level and activity of NDPK were elevated three-fold, leading to a 50- to 75% inhibition 
of cAMP-synthesis. This finding could reflect activation of the likewise increased Gi pro- 
teins. To prove the interaction of NDPK with a G protein, we transfected cells with genes 
encoding for NDPK and the atpha-subunit of the stimulatory G protein Gsalpha. Methods: 
Immortalized cells, derived from neonatal rat hearts, were stably transfected with the 
NDPK-gene NM23-H2. Overexpression of Gsalpha was induced with a recombinant ade- 
novirus. Intracellular cAMP and adenylyl cyclase activity (AC), NDPK-activity, Gsalpha 
and Gialpha in membranes were determined. Results: Overexpression of Gsalpha led to 
an increase in cAMP synthesis in all cell clones, despite the presence of the inverse ago- 
nist propranolol. This increase was strictly proportional to the level of NDPK activity in 
seven different clones. In cells with a 2.7-fold overexpression of NDPK and a 10-fold 
overexpression of Gsalpha, intracellular cAMP was increased 200-fold compared to con- 
trol cells. Stable transfection of the cells with a catalytically inactive NDPK did not 
increase cAMP-synthesis. Intracellular nucleotide concentrations were not influenced by 
the overexpression of NDPK. In crude membranes from these cells, basal, G protein 
independent AC activity was similar in all clones. However in cells overexpressing Gsal- 
pha and NDPK, activity in the presence of GDP was increased proportionally to the level 
of NDPK activity. In conclusion, these results demonstrate for the first time a functional 
interaction of NDPK with a G protein in an intact cell. 
1033-93 Antioxidant Vitamins C and E Administration in 
Smokers: Effects on Endothelial Function and Serum 
Levels of Soluble Intercellular Adhesion Molecule-I, 
Soluble Vascular Cell Adhesion Molecule, and Lipid 
Hydroperoxides 
Dimitris Tousoulis, Charalambos Antoniades, Marina Toutouza, Costas Tentolouris, 
Kyriakoula Marinou, George Goumas, Athanasios Tdkas, Costas Toutouzas, 
Christodoulos Stefanadis, Pavlos Toutouzas, Cardiology Unit Hippokration Hospital, 
Athens University Medical School, Athens, Greece. 
Background: Serum levels of soluble vascular cell adhesion molecule (sVCAM-1) and 
soluble intercellular adhesion molecule (slCAM-1), as well as lipid hydroperoxides (LPO) 
(marker of lipid peroxidation), are implicated in the pathogenesis of atherosclerosis. Pur- 
pose of this study is to investigate the effect of combined administration of antioxidant 
vitamins C and E on endothelial function, and serum levels of slCAM-1, sVCAM-1 and 
LPO, in chronic smokers. 
Methods: 36 healthy young smokers (20 males 16 females aged 36±2 years) were 
enrolled in this double blind placebo controlled study. Subjects were divided into 4 groups 
receiving vitamin C 2g/day (n=10) (group A), vitamin C 2g/day and vitamin E 4001U/day 
(n=11) (group B), vitamin C 2g/day and vitamin E 8001U/day (n=9) (group C) or placebo 
(n=6) (group D), for 4 weeks. Forearm blood flow was measured using venous occlusion 
strain gauge plethysmography. Endothelium dependent ftow mediated vasodilation 
(FMD) was expressed as the % change from baseline to post reactive hyperemia blood 
flow. Endothelium independent % change flow (NTR%) was assessed after sublingual 
nitroglycerin administration. Plasma levels of sVCAM1, and slCAM1 were determined by 
enzyme linked immunosorbent assay, while LPO was determined using a spectrephoto* 
metric assay. 
Results: Blood pressure, heart rate, body weight, basal forearm blood flow and NTR% 
were similar before and after treatment. FMD was significantly increased in groups B 
(46.6±5.5 to 74.1±9.3%, p<0.05) and C (43.6±3.9 to 74.9±4.2%, p<0.01), while remained 
unaffected in groups A and D. Serum levels of sVCAM-1 and slCAM-1 significantly 
reduced in group C (from 339±14 and 318±21 to 298±11 and 250±19 ng/ml respectively, 
p<O.O5 for both), while remained unaffected in groups A, B and D. LPO was significantly 
reduced in groups B and C (from 14.5±1.2 and 15.4±2.9 to 8.8±1.6 and 8.3±1.7 I~M 
respectively, p<0.05 for both). 
Conclusions: Chronic administration of vitamin C (2g/day) combined with vitamin E 
(8001U/day), reduces blood levels of sVCAM-1 and slCAM-1, improves endothelial func- 
tion and reduces lipid peroxidation in healthy young smokers. These findings may have 
therapeutic implications in chronic smokers 
